AEZS Stock Overview
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aeterna Zentaris Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.97 |
| 52 Week High | CA$3.38 |
| 52 Week Low | CA$1.36 |
| Beta | 2.07 |
| 1 Month Change | -4.83% |
| 3 Month Change | 3.68% |
| 1 Year Change | -39.01% |
| 3 Year Change | -92.42% |
| 5 Year Change | -98.02% |
| Change since IPO | -100.00% |
Recent News & Updates
Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk
Aug 29Aeterna slips ~10% after announcing date of reverse stock split
Jul 19Recent updates
Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk
Aug 29Aeterna slips ~10% after announcing date of reverse stock split
Jul 19Aeterna Zentaris names Michael Teifel as chief scientific officer
May 03Aeterna Zentaris (AEZS) inks option agreement to evaluate potential COVID-19 vaccine, shares up 53%
Feb 02Shareholder Returns
| AEZS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.0% | -2.5% | -3.2% |
| 1Y | -39.0% | -3.7% | 19.3% |
Return vs Industry: AEZS underperformed the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: AEZS underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| AEZS volatility | |
|---|---|
| AEZS Average Weekly Movement | 7.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: AEZS has not had significant price volatility in the past 3 months.
Volatility Over Time: AEZS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Klaus Paulini | www.zentaris.com |
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults. Aeterna Zentaris Inc. has a license agreement with University of Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and for pre-clinical development towards the potential treatment of Parkinson’s disease.
Aeterna Zentaris Inc. Fundamentals Summary
| AEZS fundamental statistics | |
|---|---|
| Market cap | US$9.44m |
| Earnings (TTM) | -US$16.55m |
| Revenue (TTM) | US$4.50m |
2.1x
P/S Ratio-0.6x
P/E RatioIs AEZS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AEZS income statement (TTM) | |
|---|---|
| Revenue | US$4.50m |
| Cost of Revenue | US$222.00k |
| Gross Profit | US$4.28m |
| Other Expenses | US$20.83m |
| Earnings | -US$16.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.41 |
| Gross Margin | 95.06% |
| Net Profit Margin | -367.99% |
| Debt/Equity Ratio | 0% |
How did AEZS perform over the long term?
See historical performance and comparison